A Bayesian piecewise exponential phase II design for monitoring a time-to-event endpoint

被引:0
|
作者
Qing, Yun [1 ,2 ]
Thall, Peter F. [1 ]
Yuan, Ying [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[2] Univ Texas Hlth Sci Ctr Houston, Dept Biostat & Data Sci, Houston, TX 77030 USA
关键词
Bayesian adaptive design; futility monitoring; go; no-go decision; interim analysis; OPTIMAL 2-STAGE DESIGNS; CLINICAL-TRIALS; SURVIVAL; SAMPLE;
D O I
10.1002/pst.2256
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A robust Bayesian design is presented for a single-arm phase II trial with an early stopping rule to monitor a time to event endpoint. The assumed model is a piecewise exponential distribution with non-informative gamma priors on the hazard parameters in subintervals of a fixed follow up interval. As an additional comparator, we also define and evaluate a version of the design based on an assumed Weibull distribution. Except for the assumed models, the piecewise exponential and Weibull model based designs are identical to an established design that assumes an exponential event time distribution with an inverse gamma prior on the mean event time. The three designs are compared by simulation under several log-logistic and Weibull distributions having different shape parameters, and for different monitoring schedules. The simulations show that, compared to the exponential inverse gamma model based design, the piecewise exponential design has substantially better performance, with much higher probabilities of correctly stopping the trial early, and shorter and less variable trial duration, when the assumed median event time is unacceptably low. Compared to the Weibull model based design, the piecewise exponential design does a much better job of maintaining small incorrect stopping probabilities in cases where the true median survival time is desirably large.
引用
收藏
页码:34 / 44
页数:11
相关论文
共 50 条
  • [11] Bayesian single-arm phase II trial designs with time-to-event endpoints
    Wu, Jianrong
    Pan, Haitao
    Hsu, Chia-Wei
    PHARMACEUTICAL STATISTICS, 2021, 20 (06) : 1235 - 1248
  • [12] A Bayesian adaptive phase III design for multi-arm trials with time-to-event endpoint for nonproportional hazards utilizing the generalized gamma distribution
    Thewarapperuma, Nadeesha
    Phadnis, Milind A.
    COMMUNICATIONS IN STATISTICS-SIMULATION AND COMPUTATION, 2024,
  • [13] Mixed response and time-to-event endpoints for multistage single-arm phase II design
    Lai, Xin
    Zee, Benny Chung-Ying
    TRIALS, 2015, 16
  • [14] Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity
    Lei, Xiudong
    Yuan, Ying
    Yin, Guosheng
    LIFETIME DATA ANALYSIS, 2011, 17 (01) : 156 - 174
  • [15] A randomized Bayesian optimal phase II design with binary endpoint
    Ding, Yang
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2023, 33 (02) : 151 - 166
  • [16] Bayesian enhancement two-stage design for single-arm phase II clinical trials with binary and time-to-event endpoints
    Shi, Haolun
    Yin, Guosheng
    BIOMETRICS, 2018, 74 (03) : 1055 - 1064
  • [17] Predicting study duration in clinical trials with a time-to-event endpoint
    Machida, Ryunosuke
    Fujii, Yosuke
    Sozu, Takashi
    STATISTICS IN MEDICINE, 2021, 40 (10) : 2413 - 2421
  • [18] Estimation of treatment effect among treatment responders with a time-to-event endpoint
    Nordland, Andreas
    Martinussen, Torben
    SCANDINAVIAN JOURNAL OF STATISTICS, 2024, 51 (03) : 1161 - 1180
  • [19] BEATS: Bayesian hybrid design with flexible sample size adaptation for time-to-event endpoints
    Bi, Dehua
    Liu, Meizi
    Lin, Jianchang
    Liu, Rachael
    STATISTICS IN MEDICINE, 2023, 42 (30) : 5708 - 5722
  • [20] Bayesian design of clinical trials using joint models for longitudinal and time-to-event data
    Xu, Jiawei
    Psioda, Matthew A.
    Ibrahim, Joseph G.
    BIOSTATISTICS, 2022, 23 (02) : 591 - 608